Search filters

BILANZ 2020 edition of the top law firms in Switzerland

VISCHER was ranked as one of the top five most recommended law firms in the following sectors: Chemicals, Medical Technology and Pharmaceuticals.

Legal 500 (EMEA 2020) - "Healthcare and Life Sciences"

"VISCHER has a strong track record in transactions in the life sciences space, in which it acts for companies, entrepreneurs and investors alike. It is also well versed in advising clients on compliance matters, administrative procedures and other regulatory matters. Stefan Kohler has longstanding experience in the sector and further advises on IP and technology law. He jointly leads the practice alongside Matthias Staehelin in Basel, who is a key contact for M&A, IPOs and financings in this space. Christian Wyss, also in Basel, has considerable knowledge in setting up contracts and assisting start-ups."

Chambers Europe 2020 - Life Sciences

Stefan Kohler advises on licensing agreements for drug development and commercialisation, with further activity in product launches. He also offers experience in pricing and reimbursement matters.

Chambers Europe 2020 - Life Sciences

Matthias Staehelin advises medical device and biopharmaceutical companies on financing mandates, with additional experience in licensing agreements.

Chambers Europe 2020 - Life Sciences

Christian Wyss covers a range of matters within the life sciences field, including licensing agreements and acquisitions. He also offers notable strength in financing mandates. One client describes him as "flexible and responsive," adding: "He is adaptable to the situation as needed in negotiations."

Best Lawyers Switzerland 2014 - 2019

Recommended for Biotechnology Law, Intellectual Property Law.

Legal 500 (EMEA 2019) - "Healthcare and Life Sciences" - Tier 1

"VISCHER is renowned for its expertise in corporate, commercial, transactional, regulatory and patent-related healthcare and biotech matters. Matthias Staehelin assisted Medartis with its initial public offering on the SIX Swiss Exchange, while Stefan Kohler acted for Novo Nordisk Pharma in its appeal against a pricing decision made by the Swiss Federal Office of Public Health concerning the client's type-two diabetes product. Christian Wyss advised Lundbeck on its €905m acquisition of Prexton Therapeutics."

Who's Who Legal (Switzerland 2019) - "Life Sciences"

"Stefan Kohler of Vischer is a well-known name in the Swiss market who possesses a strong reputation for his deep knowledge of IP regulation and contractual matters."

Chambers Europe (2019) - "Life Sciences" - Band 1

"Stefan Kohler has a strong track record in regulatory matters and is recognised for his expertise in pricing-related issues and market access questions. He assisted Philip Morris International with the regulatory and liability aspects of the launch of its new product IQOS. A source describes him as "confident and solution-oriented" and lauds his capabilities in the pharmaceutical industry."

Chambers Europe (2019) - "Life Sciences"

"Matthias Staehelin has significant experience in high-value transactional and financing work within the life sciences industry. His clients appreciate him for "his business acumen and ability to come up with practical solutions" and deem him to be a "pragmatic, assertive and solution-driven" practitioner."

You are currently offline. Some pages or content may fail to load.